Year |
Citation |
Score |
2022 |
Yang Y, Peng Z, Flores ER, Kleinerman ES. Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming. Cancers. 14. PMID 36077845 DOI: 10.3390/cancers14174310 |
0.307 |
|
2021 |
Gutiérrez LM, Valenzuela Alvarez M, Yang Y, Spinelli F, Cantero MJ, Alaniz L, García MG, Kleinerman ES, Correa A, Bolontrade MF. Up-regulation of pro-angiogenic molecules and events does not relate with an angiogenic switch in metastatic osteosarcoma cells but to cell survival features. Apoptosis : An International Journal On Programmed Cell Death. PMID 34024019 DOI: 10.1007/s10495-021-01677-x |
0.384 |
|
2020 |
Hennessy M, Wahba A, Felix K, Cabrera M, Segura MG, Kundra V, Ravoori MK, Stewart J, Kleinerman ES, Jensen VB, Gopalakrishnan V, Pena R, Quach P, Kim G, Kivimäe S, et al. Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma. International Journal of Cancer. PMID 33152115 DOI: 10.1002/ijc.33382 |
0.32 |
|
2020 |
Wolf-Dennen K, Kleinerman ES. Exosomes: Dynamic Mediators of Extracellular Communication in the Tumor Microenvironment. Advances in Experimental Medicine and Biology. 1258: 189-197. PMID 32767243 DOI: 10.1007/978-3-030-43085-6_13 |
0.437 |
|
2020 |
Koshkina N, Yang Y, Kleinerman ES. The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases. Advances in Experimental Medicine and Biology. 1258: 177-187. PMID 32767242 DOI: 10.1007/978-3-030-43085-6_12 |
0.45 |
|
2020 |
Zhou Z, Yang Y, Wang F, Kleinerman ES. Neuronal Repressor REST Controls Ewing Sarcoma Growth and Metastasis by Affecting Vascular Pericyte Coverage and Vessel Perfusion. Cancers. 12. PMID 32486064 DOI: 10.3390/Cancers12061405 |
0.42 |
|
2020 |
Wolf-Dennen K, Gordon N, Kleinerman ES. Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions. Oncoimmunology. 9: 1747677. PMID 32313728 DOI: 10.1080/2162402X.2020.1747677 |
0.448 |
|
2020 |
Zhou Y, Slone N, Chrisikos TT, Kyrysyuk O, Babcock RL, Medik YB, Li HS, Kleinerman ES, Watowich SS. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103 conventional dendritic cells. Journal For Immunotherapy of Cancer. 8. PMID 32273347 DOI: 10.1136/Jitc-2019-000474 |
0.343 |
|
2020 |
Hollomon MG, Patterson L, Santiago-O'Farrill J, Kleinerman ES, Gordon N. Knock down of Fas-Associated Protein with Death Domain (FADD) Sensitizes Osteosarcoma to TNFα-induced Cell Death. Journal of Cancer. 11: 1657-1667. PMID 32194778 DOI: 10.7150/Jca.38721 |
0.42 |
|
2020 |
Gordon NB, Kleinerman E, Sheshadri A, Blanco D, Yedururi S, Morani A, Gill JB, Harrison DJ, Herzog CE, Livingston JA, Benjamin RS, Gorlick RG, Mireles ME, Kawedia JD, Daw NC. A phase I trial of aerosol gemcitabine for the treatment of patients with solid tumors and lung metastases. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps3645 |
0.349 |
|
2019 |
Morrell MBG, Alvarez-Florez C, Zhang A, Kleinerman ES, Savage H, Marmonti E, Park M, Shaw A, Schadler KL. Vascular modulation through exercise improves chemotherapy efficacy in Ewing sarcoma. Pediatric Blood & Cancer. e27835. PMID 31136074 DOI: 10.1002/Pbc.27835 |
0.324 |
|
2019 |
Batth IS, Zaky W, Khatua S, Daw NC, Mahadeo KM, Khazal S, Albert A, Huang W, Chen D, Gill JB, Kleinerman E, Gorlick R, Li S. Abstract 1345: Automated capture and analysis of circulating tumor cells across different types of tumors in pediatric cancer patients Cancer Research. 79: 1345-1345. DOI: 10.1158/1538-7445.Sabcs18-1345 |
0.375 |
|
2018 |
Markel JE, Noore J, Emery EJ, Bobnar HJ, Kleinerman ES, Lindsey BA. Using the Spleen as an Systemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy with -PD-L1. Sarcoma. 2018: 8694397. PMID 30651716 DOI: 10.1155/2018/8694397 |
0.374 |
|
2018 |
Dhupkar P, Gordon N, Stewart J, Kleinerman ES. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Medicine. PMID 29733528 DOI: 10.1002/Cam4.1518 |
0.355 |
|
2018 |
Kleinerman ES, Yu L, Dao J, Hayes-Jordan AA, Lindsey B, Kawedia JD, Stewart J, Gordon N. Aerosol Gemcitabine after Amputation Inhibits Osteosarcoma Lung Metastases but Not Wound Healing. Sarcoma. 2018: 3143096. PMID 29610563 DOI: 10.1155/2018/3143096 |
0.344 |
|
2018 |
Livingston JA, Wang WL, Tsai JW, Lazar AJ, Leung CH, Lin H, Advani S, Daw N, Santiago-O'Farrill J, Hollomon M, Gordon NB, Kleinerman ES. Analysis of HSP27 and the autophagy marker LC3B+ puncta following preoperative chemotherapy identifies high-risk osteosarcoma patients. Molecular Cancer Therapeutics. PMID 29592877 DOI: 10.1158/1535-7163.Mct-17-0901 |
0.356 |
|
2018 |
Santiago-O'Farrill JM, Kleinerman ES, Hollomon MG, Livingston A, Wang WL, Tsai JW, Gordon NB. Phosphorylated heat shock protein 27 as a potential biomarker to predict the role of chemotherapy-induced autophagy in osteosarcoma response to therapy. Oncotarget. 9: 1602-1616. PMID 29416717 DOI: 10.18632/Oncotarget.20308 |
0.44 |
|
2017 |
Kiany S, Huang G, Kleinerman ES. Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis. Oncoimmunology. 6: e1333214. PMID 28919994 DOI: 10.1080/2162402X.2017.1333214 |
0.486 |
|
2017 |
Lewis VO, Devarajan E, Cardó-Vila M, Thomas DG, Kleinerman ES, Marchiò S, Sidman RL, Pasqualini R, Arap W. BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation. Proceedings of the National Academy of Sciences of the United States of America. PMID 28698375 DOI: 10.1073/Pnas.1704173114 |
0.471 |
|
2017 |
Aquino-López A, Senyukov VV, Vlasic Z, Kleinerman ES, Lee DA. Interferon Gamma Induces Changes in Natural Killer (NK) Cell Ligand Expression and Alters NK Cell-Mediated Lysis of Pediatric Cancer Cell Lines. Frontiers in Immunology. 8: 391. PMID 28428785 DOI: 10.3389/Fimmu.2017.00391 |
0.448 |
|
2017 |
Hu J, Bernatchez C, Zhang L, Xia X, Kleinerman ES, Hung MC, Hwu P, Li S. Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases. Cancer Immunology Research. PMID 28223282 DOI: 10.1158/2326-6066.Cir-16-0234 |
0.398 |
|
2017 |
Moonat H, Huang G, Dhupkar P, Schadler K, Gordon N, Kleinerman E. Combination of Interleukin-11Rα chimeric antigen receptor T-cells and programmed death-1 blockade as an approach to targeting osteosarcoma cells In vitro Cancer Translational Medicine. 3: 139. DOI: 10.4103/Ctm.Ctm_3_17 |
0.397 |
|
2015 |
Zhu S, Denman CJ, Cobanoglu ZS, Kiany S, Lau CC, Gottschalk SM, Hughes DP, Kleinerman ES, Lee DA. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharmaceutical Research. 32: 779-92. PMID 24203492 DOI: 10.1007/S11095-013-1231-0 |
0.429 |
|
2015 |
Yang Y, Gordon N, Kleinerman ES, Huang G. Promoting NK cell trafficking to improve therapeutic effect of NK cell therapy on osteosarcoma Journal For Immunotherapy of Cancer. 3: P24. DOI: 10.1186/2051-1426-3-S2-P24 |
0.404 |
|
2015 |
Dhupkar PM, Yu L, Gordon N, Kleinerman ES. Immune modulation through targeting PD-1/PDL-1 signaling pathway for the treatment of osteosarcoma lung metastastasis Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P218 |
0.366 |
|
2015 |
Dhupkar PM, Kleinerman E, Gordon N. Abstract A65: Immune modulation of natural killer cell adoptive transfer for the treatment of Osteosarcoma lung metastastasis: Targeting the PD-1/ PDL-1 signaling pathway Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-A65 |
0.495 |
|
2015 |
Hu J, Xia X, Kleinerman ES, Li S. Abstract 4047: CD8+T cell-mediated tumor-specific induction of the NKG2D ligands to trigger NKG2D-dependent tumor cell death in vivo Cancer Research. 75: 4047-4047. DOI: 10.1158/1538-7445.Am2015-4047 |
0.42 |
|
2015 |
Gutierrez LM, Amoros MA, Sevlever G, Podahjcer O, Cremaschi G, Kleinerman ES, Bolontrade MF. Abstract 3370: Incorporation of mesenchymal stem cells into areas of lung metastasis in an osteosarcoma model Cancer Research. 75: 3370-3370. DOI: 10.1158/1538-7445.Am2015-3370 |
0.414 |
|
2015 |
Santiago-O'Farrill JM, Hollomon M, Kleinerman E, Gordon N. Abstract 2905: HSP27 as a potential factor to determine the fate of Gemcitabine- induced autophagy in osteosarcoma: Survival vs. death Cancer Research. 75: 2905-2905. DOI: 10.1158/1538-7445.Am2015-2905 |
0.437 |
|
2014 |
Huang G, Nishimoto K, Yang Y, Kleinerman ES. Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases. Advances in Experimental Medicine and Biology. 804: 203-17. PMID 24924176 DOI: 10.1007/978-3-319-04843-7_11 |
0.408 |
|
2014 |
Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton PJ, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Meltzer P, Kirsch DG, Janeway KA, et al. Toward a drug development path that targets metastatic progression in osteosarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4200-9. PMID 24803583 DOI: 10.1158/1078-0432.Ccr-13-2574 |
0.345 |
|
2014 |
Guma SR, Lee DA, Ling Y, Gordon N, Kleinerman ES. Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. Pediatric Blood & Cancer. 61: 1362-8. PMID 24610870 DOI: 10.1002/Pbc.25019 |
0.455 |
|
2014 |
Hu J, Zhu S, Xia X, Zhang L, Kleinerman ES, Li S. CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors. Molecular Cancer. 13: 34. PMID 24565056 DOI: 10.1186/1476-4598-13-34 |
0.371 |
|
2014 |
Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li S. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Research. 74: 1645-50. PMID 24448245 DOI: 10.1158/0008-5472.Can-13-1739 |
0.353 |
|
2014 |
Zhou Z, Yu L, Kleinerman ES. EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology. Cancer. 120: 579-88. PMID 24415532 DOI: 10.1002/Cncr.28555 |
0.315 |
|
2014 |
Hamdan R, Zhou Z, Kleinerman ES. Blocking SDF-1α/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors. Molecular Cancer Therapeutics. 13: 483-91. PMID 24282276 DOI: 10.1158/1535-7163.Mct-13-0447 |
0.389 |
|
2014 |
Guma SR, Lee DA, Yu L, Gordon N, Hughes D, Stewart J, Wang WL, Kleinerman ES. Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. Pediatric Blood & Cancer. 61: 618-26. PMID 24136885 DOI: 10.1002/Pbc.24801 |
0.44 |
|
2014 |
Gordon NB, Anderson P, Guma S, Chien H, McQuinn LM, Hein JP, Zinner R, Kleinerman ES, Naing A. Abstract A82: Feasibility and safety of aerosol IL-2 in patients with lung metastases for future combination therapies for the treatment of osteosarcoma lung metastases Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-A82 |
0.457 |
|
2014 |
Kiany S, Yu L, Guindani M, Wu J, Stewart J, Kleinerman ES. Abstract LB-268: Entinostat increases susceptibility of osteosarcoma cells to NK cell lysis without suppressing NK cell cytolytic activity Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-268 |
0.467 |
|
2014 |
Gordon NB, Bitar ND, Anderson P, Guma S, Chien H, McQuinn LM, Hein JP, Zinner R, Kleinerman ES, Naing A. Abstract CT406: Aerosol interleukin-2 for the treatment of patients ≥ 12 years old with osteosarcoma lung disease: A phase I/II study Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct406 |
0.458 |
|
2014 |
Hu J, Xia X, Zhang L, Kleinerman ES, Li S. Abstract 160: CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 requires the engagement of CD80 and CD28 Cancer Research. 74: 160-160. DOI: 10.1158/1538-7445.Am2014-160 |
0.357 |
|
2013 |
Hollomon MG, Gordon N, Santiago-O'Farrill JM, Kleinerman ES. Knockdown of autophagy-related protein 5, ATG5, decreases oxidative stress and has an opposing effect on camptothecin-induced cytotoxicity in osteosarcoma cells. Bmc Cancer. 13: 500. PMID 24160177 DOI: 10.1186/1471-2407-13-500 |
0.379 |
|
2013 |
Rao-Bindal K, Koshkina NV, Stewart J, Kleinerman ES. The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases. Current Cancer Drug Targets. 13: 411-22. PMID 23410027 DOI: 10.2174/1568009611313040005 |
0.46 |
|
2013 |
Rao-Bindal K, Rao CK, Yu L, Kleinerman ES. Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts. Pediatric Blood & Cancer. 60: 575-9. PMID 23255321 DOI: 10.1002/Pbc.24412 |
0.462 |
|
2013 |
Koshkina NV, Yang G, Kleinerman ES. Inhibition of Cdc42-interacting protein 4 (CIP4) impairs osteosarcoma tumor progression. Current Cancer Drug Targets. 13: 48-56. PMID 22920438 DOI: 10.2174/1568009611309010048 |
0.483 |
|
2013 |
Naing A, Anderson P, Guma S, Chien H, McQuinn LM, Hein JP, Zinner RG, Kleinerman ES, Gordon N. Evaluation of aerosol IL-2 in sarcoma patients with lung metastases for future combination therapy with infused natural killer cells Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P251 |
0.416 |
|
2013 |
Hu J, Zhu S, Xia X, Kleinerman E, Li S. Abstract 4996: Co-stimulation of IL-12 gene delivery plus doxorubicin induces NKG2D-dependent CD8+T cell infiltration to tumors and inhibition of tumor progression. Cancer Research. 73: 4996-4996. DOI: 10.1158/1538-7445.Am2013-4996 |
0.448 |
|
2013 |
Gordon NB, Anderson P, Guma SR, Chien H, McQuinn LM, Hein JP, Zinner RG, Kleinerman ES, Naing A. Abstract C64: Clinical evaluation of aerosol IL-2 in patients with lung metastases to test feasibility and safety for future combination therapy using infused natural killer cells. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C64 |
0.437 |
|
2013 |
Santiago-O'Farrill JM, Hollomon MG, Kleinerman ES, Gordon N. Abstract A18: Autophagy as a mechanism implicated in osteosarcoma resistance to gemcitabine. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A18 |
0.463 |
|
2012 |
Rao-Bindal K, Zhou Z, Kleinerman ES. MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts. Cell Death & Disease. 3: e369. PMID 22875006 DOI: 10.1038/Cddis.2012.101 |
0.426 |
|
2012 |
Huang G, Nishimoto K, Zhou Z, Hughes D, Kleinerman ES. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Research. 72: 908-16. PMID 22186140 DOI: 10.1158/0008-5472.Can-11-1460 |
0.314 |
|
2012 |
Huang G, Yu L, Cooper LJ, Hollomon M, Huls H, Kleinerman ES. Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Research. 72: 271-81. PMID 22075555 DOI: 10.1158/0008-5472.Can-11-2778 |
0.477 |
|
2012 |
Huang G, Zhou Z, Wang H, Kleinerman ES. CAPER-α alternative splicing regulates the expression of vascular endothelial growth factor₁₆₅ in Ewing sarcoma cells. Cancer. 118: 2106-16. PMID 22009261 DOI: 10.1002/Cncr.26488 |
0.335 |
|
2012 |
Zhou Z, Kleinerman E. Abstract 1421: Down-regulation of neuronal repressor gene REST inhibits tumor growth in Ewing's sarcoma Cancer Research. 72: 1421-1421. DOI: 10.1158/1538-7445.Am2012-1421 |
0.449 |
|
2011 |
Hamdan R, Zhou Z, Kleinerman ES. SDF-1α induces PDGF-B expression and the differentiation of bone marrow cells into pericytes. Molecular Cancer Research : McR. 9: 1462-70. PMID 21911740 DOI: 10.1158/1541-7786.Mcr-11-0190 |
0.326 |
|
2011 |
Stewart KS, Kleinerman ES. Tumor Vessel Development and Expansion in Ewing's Sarcoma: A Review of the Vasculogenesis Process and Clinical Trials with Vascular-Targeting Agents. Sarcoma. 2011: 165837. PMID 21785569 DOI: 10.1155/2011/165837 |
0.337 |
|
2011 |
Koshkina NV, Rao-Bindal K, Kleinerman ES. Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases. Cancer. 117: 3457-67. PMID 21287529 DOI: 10.1002/Cncr.25884 |
0.424 |
|
2011 |
Rao-Bindal K, Kleinerman ES. Epigenetic regulation of apoptosis and cell cycle in osteosarcoma. Sarcoma. 2011: 679457. PMID 21253504 DOI: 10.1155/2011/679457 |
0.35 |
|
2011 |
Zhou Z, Stewart KS, Yu L, Kleinerman ES. Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing's sarcoma in the lung. Angiogenesis. 14: 125-33. PMID 21184173 DOI: 10.1007/S10456-010-9196-7 |
0.41 |
|
2011 |
Stewart KS, Zhou Z, Zweidler-McKay P, Kleinerman ES. Delta-like ligand 4-Notch signaling regulates bone marrow-derived pericyte/vascular smooth muscle cell formation. Blood. 117: 719-26. PMID 20944072 DOI: 10.1182/Blood-2010-05-284869 |
0.415 |
|
2011 |
Rao-Bindal K, Kleinerman ES. Abstract 5335: The histone deacetylase inhibitor MS-275 sensitizes osteosarcoma cells and osteosarcoma lung metastases to FasL-induced cell death by the downregulation c-FLIP Cancer Research. 71: 5335-5335. DOI: 10.1158/1538-7445.Am2011-5335 |
0.468 |
|
2010 |
Arndt CA, Koshkina NV, Inwards CY, Hawkins DS, Krailo MD, Villaluna D, Anderson PM, Goorin AM, Blakely ML, Bernstein M, Bell SA, Ray K, Grendahl DC, Marina N, Kleinerman ES. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4024-30. PMID 20576718 DOI: 10.1158/1078-0432.Ccr-10-0662 |
0.306 |
|
2010 |
Wang Y, Mandal D, Wang S, Kleinerman ES, Pollock RE, Lev D, Hayes-Jordan A. Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy. Cancer. 116: 3892-902. PMID 20564078 DOI: 10.1002/Cncr.25107 |
0.387 |
|
2010 |
Gordon N, Kleinerman ES. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 23: 189-96. PMID 20528149 DOI: 10.1089/Jamp.2009.0812 |
0.449 |
|
2010 |
Yu L, Su B, Hollomon M, Deng Y, Facchinetti V, Kleinerman ES. Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing's sarcomas. Cancer Research. 70: 1334-43. PMID 20124484 DOI: 10.1158/0008-5472.Can-09-2795 |
0.411 |
|
2010 |
Schadler KL, Zweidler-McKay PA, Guan H, Kleinerman ES. Delta-like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing's sarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 848-56. PMID 20103680 DOI: 10.1158/1078-0432.Ccr-09-1299 |
0.399 |
|
2010 |
Rodriguez CO, Crabbs TA, Wilson DW, Cannan VA, Skorupski KA, Gordon N, Koshkina N, Kleinerman E, Anderson PM. Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 23: 197-206. PMID 19803732 DOI: 10.1089/Jamp.2009.0773 |
0.361 |
|
2010 |
Koshkina NV, Yang G, Kleinerman ES. Abstract 5115: The role of Cdc42-interacting protein 4 (CIP4) in osteosarcoma tumorigenesis Cancer Research. 70: 5115-5115. DOI: 10.1158/1538-7445.Am10-5115 |
0.439 |
|
2009 |
Gordon N, Kleinerman ES. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases. Cancer Treatment and Research. 152: 497-508. PMID 20213411 DOI: 10.1007/978-1-4419-0284-9_29 |
0.486 |
|
2009 |
Guan H, Zhou Z, Cao Y, Duan X, Kleinerman ES. VEGF165 promotes the osteolytic bone destruction of ewing's sarcoma tumors by upregulating RANKL. Oncology Research. 18: 117-25. PMID 20066901 DOI: 10.3727/096504009789954627 |
0.4 |
|
2009 |
Huang G, Koshkina NV, Kleinerman ES. Fas expression in metastatic osteosarcoma cells is not regulated by CpG island methylation. Oncology Research. 18: 31-9. PMID 19911702 DOI: 10.3727/096504009789745638 |
0.448 |
|
2009 |
Pradelli E, Karimdjee-Soilihi B, Michiels JF, Ricci JE, Millet MA, Vandenbos F, Sullivan TJ, Collins TL, Johnson MG, Medina JC, Kleinerman ES, Schmid-Alliana A, Schmid-Antomarchi H. Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. International Journal of Cancer. Journal International Du Cancer. 125: 2586-94. PMID 19544560 DOI: 10.1002/Ijc.24665 |
0.461 |
|
2009 |
Duan X, Guan H, Cao Y, Kleinerman ES. Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Cancer. 115: 13-22. PMID 19051291 DOI: 10.1002/Cncr.24013 |
0.373 |
|
2008 |
Rodriguez NI, Hoots WK, Koshkina NV, Morales-Arias JA, Arndt CA, Inwards CY, Hawkins DS, Munsell MF, Kleinerman ES. COX-2 expression correlates with survival in patients with osteosarcoma lung metastases. Journal of Pediatric Hematology/Oncology. 30: 507-12. PMID 18797196 DOI: 10.1097/Mph.0B013E31816E238C |
0.353 |
|
2008 |
Jia SF, Guan H, Duan X, Kleinerman ES. VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. Journal of Experimental Therapeutics & Oncology. 7: 89-97. PMID 18771083 |
0.36 |
|
2008 |
Guan H, Zhou Z, Gallick GE, Jia SF, Morales J, Sood AK, Corey SJ, Kleinerman ES. Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Molecular Cancer Therapeutics. 7: 1807-16. PMID 18644993 DOI: 10.1158/1535-7163.Mct-08-0058 |
0.433 |
|
2008 |
Reddy K, Zhou Z, Schadler K, Jia SF, Kleinerman ES. Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing's tumor vessels. Molecular Cancer Research : McR. 6: 929-36. PMID 18567797 DOI: 10.1158/1541-7786.Mcr-07-2189 |
0.383 |
|
2008 |
Reddy K, Zhou Z, Jia SF, Lee TH, Morales-Arias J, Cao Y, Kleinerman ES. Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor. International Journal of Cancer. 123: 831-7. PMID 18537159 DOI: 10.1002/Ijc.23582 |
0.403 |
|
2008 |
Rennel E, Waine E, Guan H, Schüler Y, Leenders W, Woolard J, Sugiono M, Gillatt D, Kleinerman E, Bates D, Harper S. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. British Journal of Cancer. 98: 1250-7. PMID 18349828 DOI: 10.1038/Sj.Bjc.6604309 |
0.355 |
|
2008 |
Reddy K, Cao Y, Zhou Z, Yu L, Jia SF, Kleinerman ES. VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing's sarcoma vasculature. Angiogenesis. 11: 257-67. PMID 18344025 DOI: 10.1007/S10456-008-9109-1 |
0.448 |
|
2008 |
Cao Y, Jia SF, Chakravarty G, de Crombrugghe B, Kleinerman ES. The osterix transcription factor down-regulates interleukin-1 alpha expression in mouse osteosarcoma cells. Molecular Cancer Research : McR. 6: 119-26. PMID 18234967 DOI: 10.1158/1541-7786.Mcr-07-0090 |
0.384 |
|
2008 |
Graat HC, van Beusechem VW, Schagen FH, Witlox MA, Kleinerman ES, Helder MN, Gerritsen WR, Kaspers GJ, Wuisman PI. Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases. Molecular Cancer. 7: 9. PMID 18215325 DOI: 10.1186/1476-4598-7-9 |
0.38 |
|
2008 |
Quezada G, Koshkina NV, Zweidler-McKay P, Zhou Z, Kontoyiannis DP, Kleinerman ES. Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy. 52: 716-8. PMID 17984233 DOI: 10.1128/Aac.00760-07 |
0.324 |
|
2007 |
Zhou Z, Reddy K, Guan H, Kleinerman ES. VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo. Molecular Cancer Research : McR. 5: 1125-32. PMID 18025258 DOI: 10.1158/1541-7786.Mcr-07-0174 |
0.4 |
|
2007 |
Koshkina NV, Khanna C, Mendoza A, Guan H, DeLauter L, Kleinerman ES. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Molecular Cancer Research : McR. 5: 991-9. PMID 17951400 DOI: 10.1158/1541-7786.Mcr-07-0007 |
0.476 |
|
2007 |
Zhou Z, Bolontrade MF, Reddy K, Duan X, Guan H, Yu L, Hicklin DJ, Kleinerman ES. Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4867-73. PMID 17699866 DOI: 10.1158/1078-0432.Ccr-07-0133 |
0.376 |
|
2007 |
Morales-Arias J, Meyers PA, Bolontrade MF, Rodriguez N, Zhou Z, Reddy K, Chou AJ, Koshkina NV, Kleinerman ES. Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration. Cancer. 110: 1568-77. PMID 17694551 DOI: 10.1002/Cncr.22964 |
0.412 |
|
2007 |
Gordon N, Koshkina NV, Jia SF, Khanna C, Mendoza A, Worth LL, Kleinerman ES. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4503-10. PMID 17671136 DOI: 10.1158/1078-0432.Ccr-07-0313 |
0.478 |
|
2007 |
Potikyan G, Savene RO, Gaulden JM, France KA, Zhou Z, Kleinerman ES, Lessnick SL, Denny CT. EWS/FLI1 regulates tumor angiogenesis in Ewing's sarcoma via suppression of thrombospondins. Cancer Research. 67: 6675-84. PMID 17638877 DOI: 10.1158/0008-5472.Can-06-4140 |
0.415 |
|
2007 |
De Angulo G, Hernandez M, Morales-Arias J, Herzog CE, Anderson P, Wolff J, Kleinerman ES. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. Journal of Pediatric Hematology/Oncology. 29: 48-52. PMID 17230066 DOI: 10.1097/Mph.0B013E31802D3E3E |
0.368 |
|
2006 |
Jia SF, Duan X, Worth LL, Guan H, Kleinerman ES. Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing's sarcoma Cancer Gene Therapy. 13: 948-957. PMID 16763609 DOI: 10.1038/Sj.Cgt.7700968 |
0.414 |
|
2006 |
Lee TH, Bolontrade MF, Worth LL, Guan H, Ellis LM, Kleinerman ES. Production of VEGF165 by Ewing's sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature. International Journal of Cancer. 119: 839-46. PMID 16557578 DOI: 10.1002/Ijc.21916 |
0.424 |
|
2006 |
Duan X, Jia SF, Koshkina N, Kleinerman ES. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer. 106: 1382-8. PMID 16453328 DOI: 10.1002/cncr.21744 |
0.333 |
|
2005 |
Zhou Z, Lafleur EA, Koshkina NV, Worth LL, Lester MS, Kleinerman ES. Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity. Molecular Cancer Research : McR. 3: 685-91. PMID 16380506 DOI: 10.1158/1541-7786.Mcr-05-0092 |
0.761 |
|
2005 |
Gordon N, Arndt CA, Hawkins DS, Doherty DK, Inwards CY, Munsell MF, Stewart J, Koshkina NV, Kleinerman ES. Fas expression in lung metastasis from osteosarcoma patients. Journal of Pediatric Hematology/Oncology. 27: 611-5. PMID 16282894 DOI: 10.1097/01.Mph.0000188112.42576.Df |
0.441 |
|
2005 |
Asano T, Kleinerman ES, Zwelling LA, Zhou Z, Fukunaga Y. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells. Acta Oncologica (Stockholm, Sweden). 44: 240-7. PMID 16076696 DOI: 10.1080/02841860510029653 |
0.411 |
|
2005 |
Zhou Z, Guan H, Kleinerman ES. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity. Molecular Cancer Research : McR. 3: 271-5. PMID 15886298 DOI: 10.1158/1541-7786.Mcr-04-0179 |
0.356 |
|
2005 |
Guan H, Zhou Z, Wang H, Jia SF, Liu W, Kleinerman ES. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 2662-9. PMID 15814647 DOI: 10.1158/1078-0432.Ccr-04-1206 |
0.429 |
|
2005 |
Koshkina NV, Kleinerman ES. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. International Journal of Cancer. 116: 458-63. PMID 15800950 DOI: 10.1002/Ijc.21011 |
0.412 |
|
2005 |
Guan H, Jia SF, Zhou Z, Stewart J, Kleinerman ES. Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 2008-17. PMID 15756027 DOI: 10.1158/1078-0432.Ccr-04-0777 |
0.432 |
|
2005 |
Cao Y, Zhou Z, de Crombrugghe B, Nakashima K, Guan H, Duan X, Jia SF, Kleinerman ES. Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma. Cancer Research. 65: 1124-8. PMID 15734992 DOI: 10.1158/0008-5472.Can-04-2128 |
0.481 |
|
2004 |
Duan X, Jia SF, Zhou Z, Langley RR, Bolontrade MF, Kleinerman ES. Association of alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells. Clinical & Experimental Metastasis. 21: 747-53. PMID 16035619 DOI: 10.1007/S10585-005-0599-6 |
0.452 |
|
2004 |
Lafleur EA, Koshkina NV, Stewart J, Jia SF, Worth LL, Duan X, Kleinerman ES. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 8114-9. PMID 15585647 DOI: 10.1158/1078-0432.Ccr-04-0353 |
0.778 |
|
2004 |
Duan X, Zhou Z, Jia SF, Colvin M, Lafleur EA, Kleinerman ES. Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroperoxycyclophosphamide by a mechanism involving the Fas/Fas-ligand pathway. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 777-83. PMID 14760101 DOI: 10.1158/1078-0432.Ccr-1245-02 |
0.773 |
|
2003 |
Zhou Z, Zhou RR, Guan H, Bucana CD, Kleinerman ES. E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model. Molecular Cancer Therapeutics. 2: 1313-9. PMID 14707272 |
0.331 |
|
2003 |
Marco RA, Díaz-Montero CM, Wygant JN, Kleinerman ES, McIntyre BW. Alpha 4 integrin increases anoikis of human osteosarcoma cells. Journal of Cellular Biochemistry. 88: 1038-47. PMID 12616540 DOI: 10.1002/Jcb.10465 |
0.422 |
|
2003 |
Jia SF, Zhou RR, Kleinerman ES. Nude mouse lung metastases models of osteosarcoma and Ewing's sarcoma for evaluating new therapeutic strategies. Methods in Molecular Medicine. 74: 495-505. PMID 12415717 DOI: 10.1385/1-59259-323-2:495 |
0.313 |
|
2003 |
Gautam A, Waldrep JC, Kleinerman ES, Xu B, Fung YK, T'Ang A, Densmore CL. Aerosol gene therapy for metastatic lung cancer using PEI-p53 complexes. Methods in Molecular Medicine. 75: 607-18. PMID 12407767 DOI: 10.1385/1-59259-324-0:607 |
0.301 |
|
2002 |
Worth LL, Lafleur EA, Jia SF, Kleinerman ES. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncology Reports. 9: 823-7. PMID 12066216 DOI: 10.3892/Or.9.4.823 |
0.765 |
|
2002 |
Zhou RR, Jia SF, Zhou Z, Wang Y, Bucana CD, Kleinerman ES. Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16. Cancer Gene Therapy. 9: 407-13. PMID 11961663 DOI: 10.1038/Sj.Cgt.7700449 |
0.358 |
|
2002 |
Jia SF, Worth LL, Turan M, Duan Xp XP, Kleinerman ES. Eradication of osteosarcoma lung metastasis using intranasal gemcitabine. Anti-Cancer Drugs. 13: 155-61. PMID 11901308 DOI: 10.1097/00001813-200202000-00007 |
0.411 |
|
2002 |
Jia SF, Worth LL, Densmore CL, Xu B, Zhou Z, Kleinerman ES. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Therapy. 9: 260-6. PMID 11896442 DOI: 10.1038/Sj.Cgt.7700432 |
0.407 |
|
2001 |
Densmore CL, Kleinerman ES, Gautam A, Jia SF, Xu B, Worth LL, Waldrep JC, Fung YK, T'Ang A, Knight V. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes Cancer Gene Therapy. 8: 619-627. PMID 11593330 DOI: 10.1038/Sj.Cgt.7700343 |
0.383 |
|
2001 |
Zhou Z, Zwelling LA, Ganapathi R, Kleinerman ES. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta. British Journal of Cancer. 85: 747-51. PMID 11531262 DOI: 10.1054/Bjoc.2001.1966 |
0.398 |
|
2001 |
Lafleur EA, Jia SF, Worth LL, Zhou Z, Owen-Schaub LB, Kleinerman ES. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. Cancer Research. 61: 4066-71. PMID 11358827 |
0.795 |
|
2001 |
Knight V, Kleinerman ES, Waldrep JC, Giovanella BC, Gilbert BE, Koshkina NV. 9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Annals of the New York Academy of Sciences. 922: 151-63. PMID 11193890 DOI: 10.1111/J.1749-6632.2000.Tb07033.X |
0.322 |
|
2000 |
Jia SF, Worth LL, Kleinerman ES. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clinical & Experimental Metastasis. 17: 501-6. PMID 10763916 DOI: 10.1023/A:1006623001465 |
0.308 |
|
1999 |
Worth LL, Jia SF, An T, Kleinerman ES. ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity. Cancer Immunology, Immunotherapy : Cii. 48: 312-20. PMID 10473806 DOI: 10.1007/S002620050580 |
0.402 |
|
1999 |
Jia SF, An T, Worth L, Kleinerman ES. Interferon-alpha enhances the sensitivity of human osteosarcoma cells to etoposide. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 19: 617-24. PMID 10433362 DOI: 10.1089/107999099313758 |
0.345 |
|
1997 |
Murray JL, Kleinerman ES, Jia SF, Rosenblum MG, Eton O, Buzaid A, Legha S, Ross MI, Thompson L, Mujoo K, Rieger PT, Saleh M, Khazaeli MB, Vadhan-Raj S. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 19: 206-17. PMID 8811495 DOI: 10.1097/00002371-199605000-00005 |
0.3 |
|
1996 |
Asano T, An T, Mayes J, Zwelling LA, Kleinerman ES. Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. The Biochemical Journal. 307-13. PMID 8870683 DOI: 10.1042/Bj3190307 |
0.365 |
|
1996 |
Asano T, An T, Jia SF, Kleinerman ES. Altered monocyte chemotactic and activating factor gene expression in human glioblastoma cell lines increased their susceptibility to cytotoxicity. Journal of Leukocyte Biology. 59: 916-24. PMID 8691078 DOI: 10.1002/Jlb.59.6.916 |
0.466 |
|
1996 |
Asano T, Zwelling LA, An T, McWatters A, Herzog CE, Mayes J, Loughlin SM, Kleinerman ES. Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide British Journal of Cancer. 73: 1373-1380. PMID 8645582 DOI: 10.1038/Bjc.1996.261 |
0.374 |
|
1995 |
Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma American Journal of Clinical Oncology: Cancer Clinical Trials. 18: 93-99. PMID 7900714 DOI: 10.1097/00000421-199504000-00001 |
0.303 |
|
1995 |
Risin D, Kleinerman ES, Umezu Y, Pizzini RP, Balch CM, Pellis NR. Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide-phosphatidylethanolamine. Cancer Immunology, Immunotherapy : Cii. 40: 57-64. PMID 7828168 DOI: 10.1007/Bf01517236 |
0.429 |
|
1995 |
Kleinerman ES, Meyers PA, Raymond AK, Gano JB, Jia SF, Jaffe N. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: Tolerability, toxicity, and immune stimulation Journal of Immunotherapy With Emphasis On Tumor Immunology. 17: 181-193. PMID 7613644 DOI: 10.1097/00002371-199504000-00007 |
0.351 |
|
1995 |
Kleinerman ES. Biologic Therapy for Osteosarcoma Using Liposome-Encapsulated Muramyl Tripeptide Hematology/Oncology Clinics of North America. 9: 927-938. DOI: 10.1016/S0889-8588(18)30079-0 |
0.443 |
|
1994 |
Asano T, Matsushima K, Kleinerman ES. Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels. Cancer Immunology, Immunotherapy : Cii. 38: 16-22. PMID 8299114 DOI: 10.1007/Bf01517165 |
0.351 |
|
1994 |
Asano T, Kleinerman ES. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 14: 286-92. PMID 8280710 DOI: 10.1097/00002371-199311000-00006 |
0.394 |
|
1994 |
Asano T, Fujimaki W, McWatters A, An T, Matsushima K, Kleinerman ES. Effect of Adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression. Cancer Immunology, Immunotherapy : Cii. 37: 408-11. PMID 8242665 DOI: 10.1007/Bf01526798 |
0.362 |
|
1994 |
Fidler IJ, Kleinerman ES. Clinical application of phospholipid liposomes containing macrophage activators for therapy of cancer metastasis Advanced Drug Delivery Reviews. 13: 325-340. DOI: 10.1016/0169-409X(94)90018-3 |
0.363 |
|
1993 |
Fujimaki W, Griffin JR, Kleinerman ES. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation? Cancer Immunology, Immunotherapy : Cii. 36: 45-51. PMID 8422667 DOI: 10.1007/Bf01789130 |
0.352 |
|
1993 |
Maeda M, Asano T, Kleinerman ES. Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide. Cancer Immunology, Immunotherapy : Cii. 37: 203-8. PMID 8334682 DOI: 10.1007/Bf01525436 |
0.339 |
|
1993 |
Curley SA, Roh MS, Feig BW, Oyedeji C, Kleinerman ES, Klostergaard J. Mechanisms of Kupffer cell cytotoxicity in vitro against the syngeneic murine colon adenocarcinoma line MCA26 Journal of Leukocyte Biology. 53: 715-721. PMID 8315355 DOI: 10.1002/Jlb.53.6.715 |
0.455 |
|
1993 |
Kleinerman ES, Maeda M, Jaffe N. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma Cancer Treatment and Research. 62: 101-107. PMID 8096724 DOI: 10.1007/978-1-4615-3518-8_14 |
0.384 |
|
1992 |
Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: The cytokine cascade and monocyte activation following administration Journal of Clinical Oncology. 10: 1310-1316. PMID 1634921 DOI: 10.1200/Jco.1992.10.8.1310 |
0.361 |
|
1992 |
Kleinerman ES, Raymond AK, Bucana CD, Jaffe N, Harris MB, Krakoff IH, Benjamin R, Fidler IJ. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid) Cancer Immunology Immunotherapy. 34: 211-220. PMID 1537053 DOI: 10.1007/Bf01741788 |
0.362 |
|
1991 |
Kleinerman ES, Snyder JS, Jaffe N. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 9: 259-67. PMID 1988574 DOI: 10.1200/Jco.1991.9.2.259 |
0.321 |
|
1991 |
Maeda M, Knowles RD, Kleinerman ES. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro. Cancer Communications. 3: 313-21. PMID 1722107 DOI: 10.3727/095535491820873740 |
0.369 |
|
1990 |
Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J, Lamki LM, Rosenblum MG, Frost H, Gutterman JU. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 7: 1915-25. PMID 2479721 DOI: 10.1200/Jco.1989.7.12.1915 |
0.328 |
|
1990 |
Whitworth PW, Pak CC, Esgro J, Kleinerman ES, Fidler IJ. Macrophages and cancer. Cancer Metastasis Reviews. 8: 319-51. PMID 2182211 DOI: 10.1007/Bf00052607 |
0.459 |
|
1989 |
Shimizu H, Wyatt D, Knowles RD, Bucana CD, Stanbridge EJ, Kleinerman ES. Human monocytes selectively bind to cells expressing the tumorigenic phenotype Cancer Immunology Immunotherapy. 28: 185-192. PMID 2784354 DOI: 10.1007/Bf00204987 |
0.387 |
|
1989 |
Kleinerman ES, Knowles RD, Blick MB, Zwelling LA. Lithium chloride stimulates human monocytes to secrete tumor necrosis factor/cachectin. Journal of Leukocyte Biology. 46: 484-92. PMID 2553837 DOI: 10.1002/Jlb.46.5.484 |
0.312 |
|
1987 |
Lachman LB, Bakouche O, Kleinerman ES. Contradictory action of interleukin-1: cell growth and tumour cell killing. Annales De L'Institut Pasteur. Immunology. 138: 500-4. PMID 3307835 DOI: 10.1016/S0769-2625(87)80067-3 |
0.399 |
|
1985 |
Kleinerman ES, Wiltrout RH, Zicht R, Fidler IJ. Human lymphokine preparations which generate tumoricidal properties of human monocytes in vitro may be distinct from gamma interferon. Cancer Immunology, Immunotherapy : Cii. 20: 151-7. PMID 3930068 DOI: 10.1007/Bf00205682 |
0.312 |
|
1985 |
Kleinerman ES, Ceccorulli LM, Zwelling LA, Twilley T, Herberman RB, Jacob J, Gelmann EP. Activation of monocyte-mediated tumoricidal activity in patients with acquired immunodeficiency syndrome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 3: 1005-12. PMID 3926955 DOI: 10.1200/Jco.1985.3.7.1005 |
0.395 |
|
1985 |
Kleinerman ES, Fogler WE, Fidler IJ. Intracellular activation of human and rodent macrophages by human lymphokines encapsulated in liposomes. Journal of Leukocyte Biology. 37: 571-84. PMID 3920339 DOI: 10.1002/Jlb.37.5.571 |
0.331 |
|
1985 |
Koff WC, Showalter SD, Chakrabarty MK, Hampar B, Ceccorulli LM, Kleinerman ES. Human monocyte-mediated cytotoxicity against herpes simplex virus-infected cells: activation of cytotoxic monocytes by free and liposome-encapsulated lymphokines. Journal of Leukocyte Biology. 37: 461-72. PMID 3882870 DOI: 10.1002/Jlb.37.4.461 |
0.363 |
|
1984 |
Koff WC, Fidler IJ, Showalter SD, Chakrabarty MK, Hampar B, Ceccorulli LM, Kleinerman ES. Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells. Science (New York, N.Y.). 224: 1007-9. PMID 6426057 DOI: 10.1126/Science.6426057 |
0.338 |
|
1984 |
Fidler IJ, Kleinerman ES. Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2: 937-43. PMID 6379124 DOI: 10.1200/Jco.1984.2.8.937 |
0.39 |
|
1983 |
Kleinerman ES, Schroit AJ, Fogler WE, Fidler IJ. Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines. The Journal of Clinical Investigation. 72: 304-15. PMID 6348087 DOI: 10.1172/Jci110970 |
0.393 |
|
1982 |
Muchmore AV, Kleinerman ES. Spontaneous Monocyte Mediated Cytotoxicity In Man: Evidence For T Helper Activity Nk Cells and Other Natural Effector Cells. 815-819. DOI: 10.1016/B978-0-12-341360-4.50124-4 |
0.409 |
|
Show low-probability matches. |